TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer patients in curative setting, with port a cath Implantation for systemic chemotherapy, including neo-adjuvant and adjuvant chemo-immunotherapy and supportive therapy (e.g. parenteral Nutrition)~* Completion of curative Treatment with port a cath indication, operation included, regardless of a non-intravenous (subcutaneous or oral) given therapy (endocrine therapy, chemo-immunotherapy, radiotherapy)~* patients with pectoral port a cath systems~* No port a cath associated complications during curative therapy such as investigated events: persistent malfunction, thrombosis, infection of the port-a-cath (to puncture the port a cath under X-ray control is allowed except it results in diangosis of persistent malfunction)~* No therapeutic anticoagulant therapy (phenprocoumon/Marcoumar®, heparin)~* No evidence of metastatic disease~* ≥18 years~* Willing to participate~Exclusion Criteria:~* No signed informed consent~* Patients with port a cath systems other than pectoral port a cath systems (e.g. forearm port a cath System)~* Unable to attend control timepoints~* Use of the port-a-cath after the above defined curative treatment (within the investigational period)~* Willing to explant the port-a-cath~* Willing to become pregnant within one year after adjuvant treatment~* Patient with heparin-induced Thrombocytopenia (HIT)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 6 months (Type: EXPERIMENTAL): evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
- 12 months (Type: EXPERIMENTAL): evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has PTSD, diagnosed according to DSM-IV-TR™ and confirmed by the Mini International Neuropsychiatric Interview (MINI).~* The patient has a Clinician-Administered PTSD Scale Part 2 (CAPS-2) total score ≥70 at Screening and Baseline Visits.~* The reported duration of the PTSD is at least 3 months.~Exclusion Criteria:~* The index traumatic event that led to development of PTSD took place more than 15 years before screening.~* The patient has a severe personality disorder that in the investigator's opinion may interfere with the conduct of the study.~* The patient is at significant suicidal risk.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)
- Brexpiprazole (Type: EXPERIMENTAL): Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to speak and read in local language of trial hospital.~* Patients older than 18 years scheduled for elective, open repair of an iliac or abdominal aortic aneurysm distal of the Superior Mesenteric Artery (SMA) (DSAA segment C).~* Implantation of a tube or bifurcation prosthesis.~* Trans-abdominal or retroperitoneal surgical approach of aneurysm.~* Able and willing to provide written informed consent.~Exclusion Criteria:~* Not able to provide written informed consent.~* Previous open or endovascular intervention on the abdominal aorta (previous surgery on other parts of the aorta or iliac arteries is not an exclusion criterion).~* History of coagulation disorders, heparin induced thrombocytopenia (HIT), allergy for heparin or thrombocyte pathology.~* Impaired renal function with EGFR below 30 ml/min.~* Acute open AAA surgery.~* Hybrid interventions.~* Connective tissue disorders.~* Dual anti-platelet therapy, which cannot be discontinued.~* Life expectancy less than 2 years.~* Inflammatory, mycotic or infected aneurysms.~* Allergy for protamine or fish protein

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACT guided heparinization (Type: EXPERIMENTAL): Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.
- 5 000 IU of heparin (Type: ACTIVE_COMPARATOR): A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Depending on that ACT value near the end of surgery, the local protamine can be given to neutralize the effect of heparin. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Electrical Optimization of Cardiac Resynchronization Therapy in Non-responder Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient older than 18~* Patient implanted with a CRT (CRT-P or CRT-D) more than 6 months but less than 18 months before inclusion~* Non-responder patients:~Clinical criteria (Packer classification):~Lack of improvement of NYHA functional class And/or hospitalization for heart failure~Echocardiographic criteria:~Lack of improvement of LVEF \> 5points And/or reduction of LVESV \< 15%~* Patient who had signed an informed consent and is willing to comply with study requirements~* Patient covered by French national healthcare insurance~Exclusion Criteria:~* Permanent/persistant atrial fibrillation/ supra-ventricular tachycardia~* Scheduled hospitalization for major cardiac intervention or cardiac surgery in the 6 coming months~* Life-expectancy of less than 6 months~* Pregnant or breastfeeding women~* Adults under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-responders to CRT (Type: EXPERIMENTAL): Non-responders to CRT who will undergo an electrical optimization of the settings of their device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Decision Support (CDS) for Outpatient Radiology Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient medical provider with scan ordering permissions at Mount Sinai Hospital or Mount Sinai Queens~* Has an active ID in the Epic electronic medical record ordering system~Exclusion Criteria:~* Opted out of the study prior to October 13, 2015

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): Clinical Decision Support (CDS)
- Control (Type: NO_INTERVENTION): Will not receive Clinical Decision Support (CDS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: In Vitro Maturation (IVM) of Human Oocytes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Each subject must be female.~2. Each subject must have an indication for COH and IVF with or without ICSI.~3. Each subject must be willing and able to provide written informed consent for the trial~4. Each subject must be 25 to ≤42 years of age at the time of signing informed consent.~5. Each subject must have a normal cervical smear result (no atypical or abnormal cells, or in case of atypical squamous or glandular cells, no signs of malignancy; corresponding to Papanicolaou \[PAP\] I or II) obtained within 12 months prior to signing informed consent must be available~Exclusion Criteria:~1. Subject with premature ovarian failure~2. Subject with endocrine abnormalities such as hyperprolactinaemia or thyroid dysfunction~3. Subject with malformation or absence of uterus~4. Subject has tested positive for Human Immunodeficiency Virus (HIV) or Hepatitis B (by local laboratory; results obtained within 1 year prior to signing ICF are considered valid).~5. Subject with contraindication or allergy/hypersensitivity to hCG, estrogen and progesterone

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Study Arms:
- In vitro Maturation (Type: EXPERIMENTAL): in vitro maturation of immature oocytes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: STerOids in COVID-19 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the trial~* Male or Female, aged 18 years or above~* New onset of symptoms suggestive of COVID-19 e.g. new onset cough and/or fever, and/or loss of smell or taste within 7 or fewer days of participant being seen at visit 1~* In the Investigator's opinion, is able and willing to comply with all trial requirements~Exclusion Criteria:~* A known allergy to investigational medicine product (IMP) (budesonide)~* Any known contraindication to any of the IMPs (budesonide)~* Patient currently prescribed inhaled or systemic corticosteroids~* Recent use, within the previous 7 days of inhaled or systemic corticosteroids~* Patient needs hospitalisation at time of study consent~* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.~* Participants who have participated in another research trial involving an investigational product in the past 12 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled budesonide (Type: EXPERIMENTAL): Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
- Standard of care (Type: NO_INTERVENTION): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: CopiOs Posterolateral Fusion Procedure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be skeletally mature; between the ages of 21 and 75~* Patients having degenerative spondylolisthesis, stenosis with instability, or degenerative disc disease as diagnosed by radicular signs and/or imaging studies~* Patients will be medically indicated for a single-level, instrumented PLF between L2 and S1 per their surgeon~* Patient must be willing and able to comply with study requirements, including all necessary study related paperwork and follow-up visits~Exclusion Criteria:~* Use of iliac crest bone graft;~* Any previous lumbar spinal surgeries at indicated level;~* Any medical or physical condition that would preclude the potential benefit of spinal surgery;~* Use of a dynamic stabilization systems;~* Sites where stresses on void will exceed the load strength of fixation of hardware;~* Segmental defects;~* Significantly impaired vascularity proximal to the surgical site;~* Sites in direct contact with articular space;~* Soft tissue deficit not allowing closure;~* Active systemic or local infection;~* Severe degenerative bone disease;~* Patients with osteoporosis who are actively under treatment;~* Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI\>40 kg/m2);~* Active malignancy;~* Patients with a history of multiple allergies;~* Patients with known allergies to bovine collagen;~* Hypercalcemia;~* Pregnancy;~* Mental illness;~* Alcohol or drug abuse;~* Incarceration.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Single ARM - Copios Bone Filler (Type: ACTIVE_COMPARATOR): All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Determination of Coronary Flow Reserve by Dynamic Myocardial Perfusion Scintigraphy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients sent to the Nuclear Medicine Department as part of a functional evaluation by dynamic acquisition tomoscintigraphy and who will benefit from coronary angiography in the Louis Pradel Hospital hemodynamics department, depending on the results and the clinical context , outside of an emergency context.~* Patients who received the information and did not object to participate in the study~Exclusion Criteria:~* Patient with a contraindication to pharmacological stress by dipyridamole or regadenoson (acute coronary syndrome, acute pulmonary embolism, hypertension) severe pulmonary artery disease, acute aortic dissection, symptomatic aortic stenosis, hemodynamic instability, acute myocarditis, pericarditis or endocarditis, severe chronic obstructive pulmonary disease, uncompacted type III atrioventricular block, systolic pressure \<90 mmHg, Recent ischemic stroke, hypersensitivity or allergy to active ingredients or excipients)~* Patients under 18 years of age~* Patients with atrial fibrillation complete arrhythmia (ACFA)~* Patients with a history of coronary bypass grafting.~* Patients whose clinical condition requires rapid management not allowing to wait for the completion of the exams~* Pregnancy and breast feeding~* Deprivation of civil rights (guardianship, guardianship, safeguard of justice)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with or suspected coronary heart disease (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic liver disease.~* An estimated creatinine clearance of ≥ 60 mL/min.~* Serum alanine transaminase (ALT) or aspartate transaminase (AST) elevation must be above the upper limit of normal and below 5 times the upper limit of normal for patients with underlying liver disease; Child-Pugh score 5 to 9 (mild to moderate impairment).~* Patient must agree to practice effective contraception during the entire study period.~* Patient is willing to avoid strenuous physical activity from 24 hours prior to the study start, throughout the study, and for 2 weeks after the administration of the dose of study drug~* Patient is willing to avoid any alcohol consumption for the 24 hours prior to, and the 48 hours after administration of study drug; and avoid excessive alcohol consumption for the duration of the follow-up period.~* Patient must be able and willing to sign informed consent form.~Exclusion Criteria:~* Patient with clinically significant illnesses or recent hospitalization (within 60 days) which could compromise participation in the study in the judgment of the investigator, including: uncontrolled diabetes; active or uncontrolled infection; Confirmed diagnosis of HIV infection; uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia.~* Patient with any other auto immune disease, major chronic inflammatory disease or syndrome requiring significant treatment within the past year.~* Patients who are pregnant or breast feeding~* Patient receiving or has received any investigational drug within 30 days prior (or is currently using an investigational device)~* Patients with prior (within 4 weeks) or concurrent treatment with oral steroids, or protein-based therapy (i.e. TNFa)~* Patients with positive urine screen for drugs of abuse except when receiving a prescribed medication for a known indication~* Patients with Grade 2 or above hepatic encephalopathy.~* Patients who donated blood or experienced a significant blood loss (\>450 mL) within 8 weeks of screening~* Patients with a history of bleeding varices within 12 weeks of screening.~* Patients with psychiatric illness or other condition that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): RTA 402
- 2 (Type: EXPERIMENTAL): RTA 402
- 3 (Type: EXPERIMENTAL): RTA 402

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is ≥18 of age.~2. Patient is Rutherford category 2-4.~3. De novo single lesion with a diameter stenosis (%DS) of ≥50%~4. Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of \<99%.~5. Target lesion stenosis has a length of ≤100 mm based on visual assessment.~6. Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment.~7. Angiographic evidence of distal runoff defined as minimum one patent tibial artery with a straight flow to the foot.~8. Patient is willing and able to provide written informed consent prior to any study specific procedure.~9. Patient is willing and able to comply with specified follow-up evaluations at the specified times.~Exclusion Criteria:~1. Prior PTA in the intended target lesion including 10 mm proximal or distal from the intended treatment area.~2. Evidence of thrombus in the target vessel.~3. Prior ipsilateral or contralateral lower limb arterial bypass.~4. Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure.~5. Target lesion is severely calcified.~6. Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated).~7. Any planned surgery within 30 days of the study procedure.~8. Renal failure (serum creatinine \> 2.0 mg/dL).~9. Female with childbearing potential without a negative pregnancy test.~10. Patient has had an organ transplant.~11. Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study.~12. In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): GRST Peripheral Catheter System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility